^
Association details:
| Biomarker: | EGFR expression |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Excerpt:
ERBITUX® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of:...Colorectal Cancer: K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test...in combination with FOLFIRI for first-line treatment…in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy… as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.
Source:
Title:
Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Excerpt:
...The patient has been confirmed Epidermal Growth Factor Receptor expressing in tumor specimen by immunohistochemistry....
Trial ID:
Source:
Title:
Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx
Excerpt:
...- Tumor tissue available for immunohistochemical assay of epidermal growth factor receptor expression...
Trial ID:
More C2 evidence
Source:
Title:
Cetuximab (Erbitux) in combination with cisplatin or carboplatin and 5-fluorouracil in the first line treatment of subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck
Excerpt:
...• ≥18 years of age• Histologically or cytologically confirmed diagnosis of SCCHN• Recurrent and/or metastatic SCCHN, not suitable for local therapy• At least 1 bi-dimensionaly measurable lesion either by CT scan or MRI• Signed written informed consent before any study related activities are carried out• Tumor tissue available for immunohistochemical evaluation of EGFR expression• KPS of ≥70 at study entry• Effective contraception for both male and female subjects if risk of conception exists• Neutrophils ≥1500/mm³, platelet count ≥100000/mm³, and hemoglobin ≥9 g/dL• Total bilirubin ≤2 × upper limit of normality (ULN); aspartate-aminotransferase (AST) and alanine-aminotransferase (ALT) ≤3 × ULN• Creatinine clearance >60 mL/min`...
Trial ID:
Source:
Title:
Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma
Excerpt:
...Prognostic value of the CTC at baseline (EPISPOT)`Predictive value of the early progression of CTC (EPISPOT) on the overall survival`Compare for the first time the results with those obtained with the CellSearch® system`Evaluate the expression of EGFR in CTCs before and after administration of cetuximab (Erbitux) with both technologies and EPISPOT CellSearch ®`Evaluate the impact of the presence of epithelial-mesenchymal transition (EMT) marker on the prognosis...
Trial ID:
Source:
Title:
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Excerpt:
...Overall Survival (OS) (3-year Rate Reported)`Local-regional Failure (LRF) (3-year Rate Reported)`Rate of Mucositis Toxicity ≥ Grade 3`Rate of Other Toxicity ≥ Grade 3 (Not Mucositis)`Rate of Patients Who Tolerated Treatment`Rate of Deaths ≤ 30 Days After Discontinuation of Protocol Treatment`Quality of Life as Measured by European Quality of Life Questionnaire (EQ-5D)`Quality of Life as Measured by Proportion of Patients With Performance Status Scale for Head and Neck Cancer (PSS-HN) Scores ≤ 50`Quality of Life as Measured by Change From Baseline in Functional Assessment of Cancer Therapy-General (FACT-HN) at 12 Months`Correlation of Expression of Epidermal Growth Factor Receptor (EGFR) With PFS, OS, and LRF`Correlation of Pre-treatment Positron Emission Tomography (PET)/CT Maximum Standardized Uptake Value (SUVmax) With PFS, OS, and LRF`2-year Nodal Relapse Rates in Clinical N2-3 Patients by Post-treatment PET/CT Finding and Nodal Response...
Trial ID:
Source:
Title:
Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Excerpt:
...Confirmed epidermal growth factor receptor (EGFR) expression in tumor tissue by immunohistochemistry (IHC) 3....
Trial ID:
Source:
Title:
Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.
Excerpt:
...- Availability of tumour tissue for immunohistochemical analysis of EGFR expression....
Trial ID:
Source:
Title:
A Phase 1b Study of WU-NK-101 in Combination With Cetuximab
Excerpt:
...Patients may be included in this study regardless of mutation status (e.g., RAS-mutant, wild-type, or unknown status, BRAF V600E, etc.) and EGFR expression....
Trial ID:
Source:
Title:
Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery
Excerpt:
...Toxicity as assessed by NCI CTCAE v3.0`Dose modifications`Response rate (complete or partial response)`EGFR expression and downstream signaling in primary tumor and in skin samples...
Trial ID:
Source:
Title:
Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin
Excerpt:
...- Tumor tissue available for immunohistochemical staining of EGFR expression and HPV...
Trial ID:
Source:
Title:
Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy
Excerpt:
...Histologically proven metastatic or recurrent squamous cell carcinoma of the head and neck Failure to respond to initial treatment with cisplatin and paclitaxel or cisplatin and fluorouracil Bidimensionally measurable disease Sufficient tumor tissue available for immunohistochemical determination of epidermal growth factor receptor expression...
Trial ID:
Less C2 evidence
Source:
Title:
1569 - Role of NK and CD8+T cells in the antitumor effect elicited by combined treatment with radiation, tumor-specific antibody, and IL2 in a syngeneic murine model of head and neck squamous cell carcinoma
Published date:
03/10/2021
Excerpt:
MOC2 murine head and neck squamous cell carcinoma (HNSCC) cells expressing human epidermal growth factor receptor (MOC2-huEGFR+)...Combining RT and IT cetuximab and IL2 resulted in greater tumor regression and overall survival compared to single or dual treatments in mice with MOC2-huEGFR+ tumors.
